Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with
newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with
tumor proteins may help the body build an effective immune response to kill tumor cells.
Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine
therapy and temozolomide may be an effective treatment for glioblastoma.